Factor XIII deficiency: Difference between revisions
Tom.Reding (talk | contribs) m CS1 maintenance: vauthors/veditors or enumerate multiple authors/editors; WP:GenFixes on, using AWB |
Rescuing 1 sources and tagging 0 as dead.) #IABot (v2.0.9.3) (Whoop whoop pull up - 12601 |
||
| (37 intermediate revisions by 19 users not shown) | |||
| Line 1: | Line 1: | ||
{{Infobox medical condition |
{{Infobox medical condition (new) |
||
| name = Factor XIII deficiency |
|||
| image = |
|||
| caption = |
|||
| |
|||
| ⚫ | |||
| pronounce = |
|||
| field = |
|||
| synonyms = |
|||
| symptoms = |
|||
| complications = |
|||
| ⚫ | |||
| onset = |
|||
| duration = |
|||
| ⚫ | |||
| types = |
|||
| ⚫ | |||
| causes = |
|||
| risks = |
|||
| diagnosis = |
|||
| differential = |
|||
| prevention = |
|||
| treatment = |
|||
| medication = |
|||
| prognosis = |
|||
| frequency = |
|||
| deaths = |
|||
}} |
}} |
||
'''[[Factor xiii|Factor XIII]] deficiency''' occurs exceedingly rarely, causing a severe bleeding tendency. The incidence is one in a million to one in five million people, with higher incidence in areas with consanguineous marriage such as Iran that has the highest global incidence of the disorder.<ref>{{cite journal | vauthors = Dorgalaleh A, Naderi M, Hosseini MS, Alizadeh S, Hosseini S, Tabibian S| display-authors = etal| title = Factor XIII Deficiency in Iran: A Comprehensive Review of the Literature. Seminars in thrombosis and hemostasis | volume = 41 | issue = 3 (41) | pages = 323–329 | date=2015}}</ref> Most are due to mutations in the A subunit gene (located on chromosome 6p25-p24). This mutation is inherited in an autosomal recessive fashion. |
'''[[Factor xiii|Factor XIII]] deficiency''' occurs exceedingly rarely, causing a severe bleeding tendency. The incidence is one in a million to one in five million people, with higher incidence in areas with consanguineous marriage such as Iran that has the highest global incidence of the disorder.<ref>{{cite journal | vauthors = Dorgalaleh A, Naderi M, Hosseini MS, Alizadeh S, Hosseini S, Tabibian S| display-authors = etal| title = Factor XIII Deficiency in Iran: A Comprehensive Review of the Literature. Seminars in thrombosis and hemostasis | volume = 41 | issue = 3 (41) | pages = 323–329 | date=2015}}</ref> Most are due to mutations in the A subunit gene (located on chromosome 6p25-p24). This mutation is inherited in an autosomal recessive fashion. |
||
| Line 18: | Line 27: | ||
Deficiency of Factor XIII leads to defective cross-linking of [[fibrin]] and vulnerability to late re-bleeds when the primary [[Homeostasis|hemostatic]] plug is overwhelmed. Bleeding tendencies similar to hemophiliacs develop, such as [[hemarthroses]] and deep tissue bleeding. |
Deficiency of Factor XIII leads to defective cross-linking of [[fibrin]] and vulnerability to late re-bleeds when the primary [[Homeostasis|hemostatic]] plug is overwhelmed. Bleeding tendencies similar to hemophiliacs develop, such as [[hemarthroses]] and deep tissue bleeding. |
||
As Factor XIII is composed of two subunit protein, A and B, for which the genes are located on different chromosomes, administration of [[Recombinant DNA|recombinant]] A subunit improves clot stability and is becoming a therapeutic option for patients with this condition.<ref name="lovejoy">{{cite journal |vauthors=Lovejoy A, Reynolds T, Visich J, Butine M, Young G, Belvedere M, Blain R, Pederson S, Ishak L, Nugent D | title = Safety and pharmacokinetics of recombinant factor XIII-A2 administration in patients with congenital factor XIII deficiency. | journal = Blood | volume = 108 | issue = 1 | pages = 57–62 | year = 2006 | pmid = 16556896 | doi = 10.1182/blood-2005-02-0788}}</ref><ref name="Recombinant Factor XIII">{{cite web | title = Recombinant Factor XIII. | year = 2010 | url = http://clinicaltrials.gov/ct2/results?intr=%22Recombinant+factor+XIII%22}}</ref> |
As Factor XIII is composed of two subunit protein, A and B, for which the genes are located on different chromosomes, administration of [[Recombinant DNA|recombinant]] A subunit improves clot stability and is becoming a therapeutic option for patients with this condition.<ref name="lovejoy">{{cite journal |vauthors=Lovejoy A, Reynolds T, Visich J, Butine M, Young G, Belvedere M, Blain R, Pederson S, Ishak L, Nugent D | title = Safety and pharmacokinetics of recombinant factor XIII-A2 administration in patients with congenital factor XIII deficiency. | journal = Blood | volume = 108 | issue = 1 | pages = 57–62 | year = 2006 | pmid = 16556896 | doi = 10.1182/blood-2005-02-0788| doi-access = free }}</ref><ref name="Recombinant Factor XIII">{{cite web | title = Recombinant Factor XIII. | year = 2010 | url = http://clinicaltrials.gov/ct2/results?intr=%22Recombinant+factor+XIII%22}}</ref> |
||
==Signs and symptoms== |
|||
== Therapy options == |
|||
{{Empty section|date=November 2021}} |
|||
== Diagnosis == |
|||
Bleeding manifestation with normal PT, aPTT, TT, BT, and CT is suspected as factor XIII Deficiency. |
|||
Confirmatory test is urea lysis test. |
|||
If clot is easily lysed in 5(M) urea solution then unstable clot and factor-XIII deficiency is confirmed.{{citation needed|date=June 2020}} |
|||
== Treatment == |
|||
=== Fresh frozen plasma and cryoprecipitate === |
=== Fresh frozen plasma and cryoprecipitate === |
||
Fresh frozen plasma and cryoprecipitate are the mainstay of therapy for Factor XIII deficiency, but carry risk related to transfusion. |
Fresh frozen plasma and cryoprecipitate are the mainstay of therapy for Factor XIII deficiency, but carry risk related to transfusion.{{cn|date=November 2021}} |
||
=== Factor XIII concentrates === |
=== Factor XIII concentrates === |
||
Two commercially produced factor XIII concentrates are currently available in Europe, one manufactured by Bio Products Laboratory (BPL) and only available in the United Kingdom. The other, Fibrogammin-P, is produced by Beringwerke of Germany. In the U.S. FXIII concentrate is only available under the Federal Drug Administration's Investigational New Drug (IND) Program, or through clinical trial.<ref>http://www.hemophilia.org/NHFWeb/MainPgs/MainNHF.aspx?menuid=71&contentid=58</ref> |
Two commercially produced factor XIII concentrates are currently available in Europe, one manufactured by Bio Products Laboratory (BPL) and only available in the United Kingdom. The other, Fibrogammin-P, is produced by Beringwerke of Germany. In the U.S. FXIII concentrate is only available under the Federal Drug Administration's Investigational New Drug (IND) Program, or through clinical trial.<ref>{{Cite web | url=http://www.hemophilia.org/NHFWeb/MainPgs/MainNHF.aspx?menuid=71&contentid=58 |title = Factor XIII|date = 2014-03-05}}</ref> |
||
=== Recombinant factor XIII === |
=== Recombinant factor XIII === |
||
Recombinant factor XIII (rFXIII) is the only drug alternative to receiving blood transfusions, the traditional treatment for factor XIII deficiency. [[Novo Nordisk]]’s rFXIII, [[catridecacog]], was approved by the [[US Food and Drug Administration]] in 2014. Although it is a recombinant protein, rFXIII subunit A is identical in structure and function to the A subunit of factor XIII naturally produced in the body by healthy individuals.<ref>{{cite journal | author = Muszbek, |
Recombinant factor XIII (rFXIII) is the only drug alternative to receiving blood transfusions, the traditional treatment for factor XIII deficiency. [[Novo Nordisk]]’s rFXIII, [[catridecacog]], was approved by the [[US Food and Drug Administration]] in 2014. Although it is a recombinant protein, rFXIII subunit A is identical in structure and function to the A subunit of factor XIII naturally produced in the body by healthy individuals.<ref>{{cite journal | author = Muszbek, Laszlo| title = Blood coagulation factor XIII: structure and function. | journal = [[Thrombosis Research]] | volume = 94 | pages = 271–305 | year = 1999 | doi = 10.1016/S0049-3848(99)00023-7 | pmid = 10379818 | issue = 5|display-authors=etal}}</ref> These patients need exogenous subunit A of factor XIII since they have a mutation which prevents production of the A subunit. However, since the B-subunit is located on a separate chromosome, factor XIII deficient patients actually produce the B-subunit normally. When these two subunits interact in the plasma, the enzyme is activated and can act within the clotting cascade.<ref name="lovejoy"/> rFXIII acts by inhibiting [[fibrinolysis]] factors which enzymatically cleave the fibrin matrix, leading to the ultimate formation of clots.{{cn|date=April 2022}} |
||
rFXIII is synthetically bio-engineered through a yeast expression system and administered intravenously. In clinical trials, the drug was administered once every four weeks or administered on-demand in order to treat bleeding episodes.<ref>{{cite web | author = Clinical Trials at Novo Nordisk | title = Evaluation of Recombinant Factor XIII for Prevention of Bleeding in Patients with FXIII Inherited Deficiency. | year = 2010 | url = http://novonordisk-trials.com/website/search/trial-registry-details.aspx?id=1678&p=1&search=t}}</ref> The introduction of rFXIII as a treatment for factor XIII deficiency eliminates the risk of pathogenic infection present in plasma-based treatments. rFXIII treatment would also not be dependent on blood donations, consequently increasing availability and product quality. One of the biggest fears in developing rFXIII was that the body would mount an immune-response to the protein; however, several safety and [[ |
rFXIII is synthetically bio-engineered through a yeast expression system and administered intravenously. In clinical trials, the drug was administered once every four weeks or administered on-demand in order to treat bleeding episodes.<ref>{{cite web | author = Clinical Trials at Novo Nordisk | title = Evaluation of Recombinant Factor XIII for Prevention of Bleeding in Patients with FXIII Inherited Deficiency. | year = 2010 | url = http://novonordisk-trials.com/website/search/trial-registry-details.aspx?id=1678&p=1&search=t | access-date = 2010-11-29 | archive-date = 2022-11-12 | archive-url = https://web.archive.org/web/20221112030108/https://www.novonordisk-trials.com/ | url-status = dead }}</ref> The introduction of rFXIII as a treatment for factor XIII deficiency eliminates the risk of pathogenic infection present in plasma-based treatments. rFXIII treatment would also not be dependent on blood donations, consequently increasing availability and product quality. One of the biggest fears in developing rFXIII was that the body would mount an immune-response to the protein; however, several safety and [[pharmacokinetics]] studies have reported no [[immunogenic]] response to rFXIII or associated yeast products.<ref name="lovejoy"/> |
||
==See also== |
==See also== |
||
| Line 38: | Line 54: | ||
==References== |
==References== |
||
{{Reflist}} |
{{Reflist}} |
||
== External links == |
|||
{{Medical resources |
|||
| ⚫ | |||
| ⚫ | |||
| ICD10 = {{ICD10|D|68|2|d|65}} |
|||
| ICD9 = {{ICD9|286.3}} |
|||
| ICDO = |
|||
| OMIM = 134570 |
|||
| ⚫ | |||
| MedlinePlus = |
|||
| ⚫ | |||
| ⚫ | |||
| MeshID = D005177 |
|||
| SNOMED CT = 18604004 |
|||
}} |
|||
| ⚫ | |||
[[Category:Coagulopathies]] |
[[Category:Coagulopathies]] |
||
Latest revision as of 00:22, 6 March 2023
| Factor XIII deficiency | |
|---|---|
| Specialty | Hematology  |
Factor XIII deficiency occurs exceedingly rarely, causing a severe bleeding tendency. The incidence is one in a million to one in five million people, with higher incidence in areas with consanguineous marriage such as Iran that has the highest global incidence of the disorder.[1] Most are due to mutations in the A subunit gene (located on chromosome 6p25-p24). This mutation is inherited in an autosomal recessive fashion.
Deficiency of Factor XIII leads to defective cross-linking of fibrin and vulnerability to late re-bleeds when the primary hemostatic plug is overwhelmed. Bleeding tendencies similar to hemophiliacs develop, such as hemarthroses and deep tissue bleeding.
As Factor XIII is composed of two subunit protein, A and B, for which the genes are located on different chromosomes, administration of recombinant A subunit improves clot stability and is becoming a therapeutic option for patients with this condition.[2][3]
Signs and symptoms
[edit]![[icon]](/wiki/File:Wiki_letter_w_cropped.svg){kind=small} | This section is empty. You can help by adding to it. (November 2021) |
Diagnosis
[edit]Bleeding manifestation with normal PT, aPTT, TT, BT, and CT is suspected as factor XIII Deficiency. Confirmatory test is urea lysis test. If clot is easily lysed in 5(M) urea solution then unstable clot and factor-XIII deficiency is confirmed.[citation needed]
Treatment
[edit]Fresh frozen plasma and cryoprecipitate
[edit]Fresh frozen plasma and cryoprecipitate are the mainstay of therapy for Factor XIII deficiency, but carry risk related to transfusion.[citation needed]
Factor XIII concentrates
[edit]Two commercially produced factor XIII concentrates are currently available in Europe, one manufactured by Bio Products Laboratory (BPL) and only available in the United Kingdom. The other, Fibrogammin-P, is produced by Beringwerke of Germany. In the U.S. FXIII concentrate is only available under the Federal Drug Administration's Investigational New Drug (IND) Program, or through clinical trial.[4]
Recombinant factor XIII
[edit]Recombinant factor XIII (rFXIII) is the only drug alternative to receiving blood transfusions, the traditional treatment for factor XIII deficiency. Novo Nordisk’s rFXIII, catridecacog, was approved by the US Food and Drug Administration in 2014. Although it is a recombinant protein, rFXIII subunit A is identical in structure and function to the A subunit of factor XIII naturally produced in the body by healthy individuals.[5] These patients need exogenous subunit A of factor XIII since they have a mutation which prevents production of the A subunit. However, since the B-subunit is located on a separate chromosome, factor XIII deficient patients actually produce the B-subunit normally. When these two subunits interact in the plasma, the enzyme is activated and can act within the clotting cascade.[2] rFXIII acts by inhibiting fibrinolysis factors which enzymatically cleave the fibrin matrix, leading to the ultimate formation of clots.[citation needed]
rFXIII is synthetically bio-engineered through a yeast expression system and administered intravenously. In clinical trials, the drug was administered once every four weeks or administered on-demand in order to treat bleeding episodes.[6] The introduction of rFXIII as a treatment for factor XIII deficiency eliminates the risk of pathogenic infection present in plasma-based treatments. rFXIII treatment would also not be dependent on blood donations, consequently increasing availability and product quality. One of the biggest fears in developing rFXIII was that the body would mount an immune-response to the protein; however, several safety and pharmacokinetics studies have reported no immunogenic response to rFXIII or associated yeast products.[2]
See also
[edit]References
[edit]- ^ Dorgalaleh A, Naderi M, Hosseini MS, Alizadeh S, Hosseini S, Tabibian S, et al. (2015). "Factor XIII Deficiency in Iran: A Comprehensive Review of the Literature. Seminars in thrombosis and hemostasis". 41 (3 (41)): 323–329.
{{cite journal}}: Cite journal requires|journal=(help) - ^ a b c Lovejoy A, Reynolds T, Visich J, Butine M, Young G, Belvedere M, Blain R, Pederson S, Ishak L, Nugent D (2006). "Safety and pharmacokinetics of recombinant factor XIII-A2 administration in patients with congenital factor XIII deficiency". Blood. 108 (1): 57–62. doi:10.1182/blood-2005-02-0788. PMID 16556896.
- ^ "Recombinant Factor XIII". 2010.
- ^ "Factor XIII". 2014-03-05.
- ^ Muszbek, Laszlo; et al. (1999). "Blood coagulation factor XIII: structure and function". Thrombosis Research. 94 (5): 271–305. doi:10.1016/S0049-3848(99)00023-7. PMID 10379818.
- ^ Clinical Trials at Novo Nordisk (2010). "Evaluation of Recombinant Factor XIII for Prevention of Bleeding in Patients with FXIII Inherited Deficiency". Archived from the original on 2022-11-12. Retrieved 2010-11-29.